Strategy
Inside the Mind of the CEO
12/18/10
The Western world is stuck in a “new normal” marked by sluggish growth and a hesitancy to invest, as today’s CEOs have been “shellshocked by crisis,” writes Monitor co-founder Joseph Fuller in an article for Newsweek.
“It is not just the world that’s uncertain, it’s the managerial class itself that has lost confidence in its ability to make decisions in a world shaped by volatility and shock,” Fuller writes. As a result, companies are making conservative, incremental investments and changes, or marshaling cash in fear of scarce access to financing.
While this has significant implications for the global economy, it also represents a huge opportunity for CEOs who are able to “stare down their fear and act,” Fuller writes. “The ‘new normal’ has changed the nature of opportunities, not proscribed them. The greatest opportunity may come to those whose competitors are still stuck in their paralysis.” Read more...
“It is not just the world that’s uncertain, it’s the managerial class itself that has lost confidence in its ability to make decisions in a world shaped by volatility and shock,” Fuller writes. As a result, companies are making conservative, incremental investments and changes, or marshaling cash in fear of scarce access to financing.
While this has significant implications for the global economy, it also represents a huge opportunity for CEOs who are able to “stare down their fear and act,” Fuller writes. “The ‘new normal’ has changed the nature of opportunities, not proscribed them. The greatest opportunity may come to those whose competitors are still stuck in their paralysis.” Read more...
China, the Life Sciences Leader of 2020
10/11/10
In Monitor’s recent report, “China, the Life Sciences Leader of 2020,” George Baeder and Michael Zielenziger find that China is poised to become the global leader in life science discovery and innovation within the next decade.
At a time when the global life sciences and pharmaceutical industries are beset by major challenges, including patent cliffs, skyrocketing costs of drug approvals and failures in key trials for potentially landmark new drugs, China has developed a strategy of targeted government investments. Through a variety of national and regional programs, China is spending billions on a new health care “safety net,” encouraging the growth of life science parks and startups, financing the development of a high-quality research infrastructure and luring back tens of thousands of Western-educated Chinese researchers. Read more... (PDF 7MB)
At a time when the global life sciences and pharmaceutical industries are beset by major challenges, including patent cliffs, skyrocketing costs of drug approvals and failures in key trials for potentially landmark new drugs, China has developed a strategy of targeted government investments. Through a variety of national and regional programs, China is spending billions on a new health care “safety net,” encouraging the growth of life science parks and startups, financing the development of a high-quality research infrastructure and luring back tens of thousands of Western-educated Chinese researchers. Read more... (PDF 7MB)